Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8 + T-Cell-Dependent Tumor Activity.

MLA

Watanabe, Tsubasa, et al. “Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8 + T-Cell-Dependent Tumor Activity.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 4, Feb. 2020, pp. 945–56. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-19-0476.

APA

Watanabe, T., Gaedicke, S., Guffart, E., Firat, E., & Niedermann, G. (2020). Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8 + T-Cell-Dependent Tumor Activity. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(4), 945–956. https://doi.org/10.1158/1078-0432.CCR-19-0476

Chicago

Watanabe, Tsubasa, Simone Gaedicke, Elena Guffart, Elke Firat, and Gabriele Niedermann. 2020. “Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8 + T-Cell-Dependent Tumor Activity.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26 (4): 945–56. doi:10.1158/1078-0432.CCR-19-0476.